MacroGenics Has $287.7 Million To Advance Cancer Drugs — Its Funding Outlook Runs Through 2028
Manufacturing-sale proceeds and partner payments added cash as smaller milestones pushed quarterly revenue lower.
MacroGenics, which develops antibody-based cancer medicines, reported $287.7 million in cash and investments Thursday and kept its funding outlook through 2028. The earnings release attached to its SEC filing put the unaudited September 30 balance above the $189.9 million held at year-end 2025.
Bora Sale Adds $119.6 Million
MacroGenics received $119.6 million during the third quarter from Bora, the buyer of its manufacturing operations. Other cash receipts included a $24.5 million regulatory milestone payment from Sanofi and a $10.0 million licensing-option payment from Gilead.
President and CEO Eric Risser said MacroGenics had “generated approximately $290 million in non-dilutive capital over the past 12 months,” or funding without issuing shares.
The company expects its September cash and investments, together with anticipated partner payments, to cover operations through 2028. That outlook includes money it expects to receive, alongside funds already on hand.
MacroGenics builds experimental treatments using its antibody technology and earns collaboration revenue from drugmakers including Gilead. Its business also includes income from approved medicines it licensed or sold, including ZYNYZ, MARGENZA and TZIELD.
Smaller Milestones Reverse Quarterly Profit
Third-quarter revenue fell to $18.7 million from $53.0 million a year earlier. MacroGenics attributed the decline mainly to the comparison between $50.0 million of milestone revenue under its Provention agreement with Sanofi in 2025 and $10.0 million from Gilead's option exercise in 2026.
A $5.3 million increase in ZYNYZ royalties partly offset that decline. The quarter ended with a $20.1 million loss, or $0.32 per share, compared with a $16.8 million profit, or $0.27 per share, a year earlier.
Research spending decreased to $30.6 million from $32.7 million. MacroGenics attributed the reduction to lower spending on several programs and manufacturing activities, partly offset by higher costs for MGC026, MGC028 and MGC030 clinical work, among other development efforts.
Administrative spending fell to $8.4 million from $9.9 million, which the company attributed mainly to lower personnel costs, including stock-based pay.
MGC028 Moves Toward Dose Comparison
MacroGenics completed dose escalation in the early-stage MGC028 trial and selected a cancer indication for further testing. It plans to compare two doses by year-end 2026 and intends to provide interim safety and efficacy results in the first half of 2027.
The company also began treating patients with MGC030 in an early-stage study of advanced solid tumors. Both candidates are antibody-drug conjugates—treatments that link an antibody to a drug.
MGC026's development builds on interim results announced October 23: a 27% response rate among 22 heavily pretreated head-and-neck cancer patients. That included four confirmed partial responses and two unconfirmed partial responses; no patient in that group stopped treatment for a treatment-related reason.
MacroGenics expects to finish enrolling the 40-patient MGC026 head-and-neck cancer cohort by year-end 2026, with updated results expected in mid-2027. For lorigerlimab, its experimental treatment for advanced gynecologic cancers, it expects to complete enrollment of 20 clear-cell cancer patients at a lower dose by year-end 2026.
MacroGenics expects updated lorigerlimab results in the first half of 2027, alongside its planned MGC028 interim update.
Sources
- 8-K Filing — MACROGENICS INC (MGNX) — SEC EDGAR
- Exhibit exhibit99-1earningspressre.htm — MACROGENICS INC 8-K exhibit — SEC EDGAR
- MacroGenics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate Progress — Yahoo Finance
- MacroGenics Reports Third Quarter 2026 Financial Results — globenewswire.com
- 8-K filed 2026-10-23 — MACROGENICS INC (earlier disclosure) — SEC EDGAR